Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Zynerba

* Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024
* European Commission granted orphan... | March 29, 2023

Related Keywords

Chicago ,Illinois ,United States ,Lincoln Park ,Jim Fickenscher ,Peter Vozzo ,Armando Anido ,European Medicines Agency ,American College Of Neuropsychopharmacology ,Silicon Valley Bank ,Exchange Commission ,Drug Administration ,Zynerba Pharmaceuticals Inc ,Hc Wainwright Co ,European Commission ,Ladenburg Thalmann Co ,Trademark Office ,Vp Corporate Development ,Zynerba Pharmaceuticals ,Lincoln Park Capital Fund ,Nasdaq ,Canaccord Genuity ,Cantor Fitzgerald Co ,Chief Executive Officer ,Fragilex Syndrome ,New Drug Application ,Marketing Authorization Application ,Neurodevelopmental Disorders ,Press Release ,Fragilex Syndrome With Cannabidiol ,Annual Meeting ,Pediatric Anxiety Rating Scale ,Mood Scale ,Aberrant Behavior Checklist ,Syndrome With Cannabidiol ,Full Year ,Controlled Equity ,Purchase Agreement ,Park Capital Fund ,Fast Track ,Private Securities Litigation Reform Act ,Medicines Agency ,Stockholder Equity Current ,Nc Stock Exchange ,News ,Information ,Enrollment ,Ontinues ,N ,Confirmatory ,Pivotal ,Hase , ,Trial ,F ,Ygel ,Patients ,Ith ,Fragile ,Topline ,Results ,Xpected ,European ,Commission ,Ranted Zyne Us98986x1090 ,